Article Listing - New combo therapies will take center stage in AMI, says DR
Benefits of Diane 35 and generics outweigh risks in specific patient group, says EMA unit; other actions
17 May 2013
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefits of Diane 35 (cyproterone acetate 2mg, ethinylestradiol 35mcg) and its generics outweigh the risks, provided that several measures are taken to minimize the risk of thromboembolism (formation of blood clots in the veins and arteries).
New study shows UCB's Neupro reduces NSBP in RLS patient
17 May 2013
Leading Belgian drugmaker UCB (Euronext Brussels: UCB) today (May 17) announced data from a double-blind, placebo-controlled study that found that Neupro (rotigotine transdermal system) reduced total nocturnal systolic blood pressure (NSBP) elevations associated with periodic limb movements during sleep (PLMS) and total PLMS in patients with idiopathic moderate-to-severe Restless Legs Syndrome (RLS)/Willis-Ekbom disease. The data were presented at the Annual Scientific Meeting of the American Society of Hypertension, May 15-18, 2013.
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
17 May 2013
German family-owned drug major Boehringer Ingelheim said today (May 17) that it is updating health care professionals (HCPs) and patients that the transition to Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of chronic obstructive pulmonary disease (COPD) is nearly complete.
European pharmacist organizations make joint call for action on medicines shortages
17 May 2013
The representative organizations for European community, hospital and industrial pharmacists have issued a joint call for action by governments, regulators and the European Commission to tackle the growing problem of medicines shortages.
GlaxoSmithKline reveals new research on health care models in developing countries
17 May 2013
UK pharma giant GlaxoSmithKline (LSE: GSK) and the International Center for Social Franchising (ICSF) have undertaken the first ever global in-depth study to identify health care innovations in developing countries that have the potential to be replicated to increase access to affordable medicine.
AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease
17 May 2013
US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext: GLPG) on their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase II program in Crohn's disease, which is designed to facilitate rapid progression into Phase III.
Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
17 May 2013
French drug major Sanofi (Euronext: SAN) and NYSE: SNY) this morning (May 17) revealed that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups.
Neovacs moving forward in rheumatoid arthritis, say analysts
17 May 2013
French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead product TNFalpha-Kinoid in rheumatoid arthritis (RA). The strategy is designed to maintain momentum of the programme while it seeks a partner.
Infectious disease treatments market driven by growth in middle-income to low-income countries
17 May 2013
The infectious disease treatments market increased at a compound annual growth rate (CAGR) of 6.9% between 2008 and 2012, reaching a value of around $19 billion at the end of 2012, according to a new report added to the offering of Companiesandmarkets.com.
Bristol-Myers' data on Yervoy and nivolumab causes a stir
17 May 2013
Release of abstracts of presentations to be made at the forthcoming49th Annual Meeting of the American Society of Clinical Oncology (ASCO) meeting by US drug major Bristol-Myers Squibb (NYSE: BMY), notably extended follow-up from a Phase nivolumab study, results from Phase I nivolumab and Yervoy (ipilimumab; which was approved as a treatment for melanoma in 2011) combination study, and five-year survival data from four Phase II Yervoy studies, caused a great deal of excitement in the investment community.
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
